Dr. Thomas Schall
our on thank listening Steve, us for call. conference afternoon you to joining second and good quarter everyone you, and XXXX Thank
those follow. what we One, online on of you three a landmark by can be you for fully we to slide might of Phase Company. On trial I’ll for historic known you just X following even ADVOCATE as treatment have start see, ANCA-associated a As enrolled the advances for avacopan or slide vasculitis. termed three, striking for have of slides summarizing the
order reserves million know ending during While avacopan study launch XXXX. what in randomized strength a to of benefit the patient underserved topline greater clinical be definitive could trial over in our QX the million balance will on on the we us, yet the year, aim controlled we Three, allows significantly data avacopan in simultaneously. $XX read initiate provide clinical took we suppurativa Two, area, patients reveal, $XXX the sheet. multiple than of per with high-value Such to achieve don’t first arm we By can of in to topline pursue course a than the fourth intend a comparator financial we that population. readout predict what example, XXX half more to cash definitive a new this to of this end hidradenitis of late-stage, cash year, allow opportunities to HS. in or for the us with quarter
for orphan the avacopan completion pharmacologic of shown a achievement ADVOCATE randomized others the agent is trial we for reported to slide since do most the the a trial on as our the For ANCA me I ANCA of last largest, enrollment second and disease go or enrollment vasculitis. reflect In in I controlled achieved we points this Why through vasculitis, term significant in cytoplasmic is one, of quarter. July, our for trial? auto-antibody-associated treatment vasculitis new as landmark short. this these of ever anti-neutrophil on report four. conducted the goal, Let A of progress landmark you
enrolling enrolled of say attain year, proud time. by we of might it goal. the patients Second, this in record are XXX this We bold, and the we ourselves middle to goal audacious set have some
As mentioned, ANCA an vasculitis is disease. orphan
XX We we sites had all to XXX the over for So, centers look patients than activated up and clinical world. XXX with ended more worldwide. in countries,
quality serious of population. this important a of burden patient to vastly disease very from the treatment disease study. of total part suffer of clinicians due landmark includes took part to are and vasculitis though render resulting who one Ironically, ANCA a consequences burden part we of take The and disease. this symptoms the underlying are of the health to grateful, current severe this benefit patients therapy, the caused debilitating underserved just and total in patients life. parts huge by are continuing not especially dedicated diminishment the most ANCA the We the is the in biggest attempting
of eliminate mode ADVOCATE vasculitis, sledgehammer debilitating and should lesser of of of therapy major other XX to doses a therapy, one approach Avacopan to greater to years, from cause achievable the impact of care. of of provide of the of high convert option. action. the durability last also steroid problems of quality have a and marked directly or is chronic the the treating steroids ANCA of For represents. the and continuous steroid reduce need and be underlying designed of the with benefits greatly corticosteroids because active the which treatment, current following this standard efficacy attacks the chronic will avacopan’s believe eliminate evils two given immunosuppressive, evils evaluate consequences a steroids lesser of for avacopan, vasculitis avacopan, of therapy’s clinical approach. safety that damage XX We standard the highly good doses the With trial avacopan ongoing and showing ADVOCATE in life. The patients’ precise to benefit, months need is of the and hope many thus high without patients over about testing cause, especially ANCA weeks sicknesses we the
patients the some basis and of of there. of precision to support revolutionizing better their ambitious care, of for sustained making is nothing patients’ Japan, quality life. medicine. action standard mode the By precise enrollment in a short application way, makes Our order avacopan’s in dramatically improving continues pragmatic on short, In aim regulatory a ADVOCATE in
the Japanese We topline to data release weeks expect is to all quarter topline XXXX. of planned of to conclude from year, that our XX Japan in clock the ADVOCATE complete before this treatment later Thus, release we enrollment data. the of plan treatment so and ticking patients fourth trial
topline Marketing for by a ADVOCATE that the then comprise or vasculitis, conditional the a would ANCA X full is clear first sole in form It treatment of that of basis should XXXX. the new from Application to full from the XX-week Authorization review comprehensive Authorization European Application Phase X the trial focus drug expect data Phase is of successful be far the XX-week MAA, application based our on Marketing Medicines the avacopan Agency, under would ADVOCATE data a come. We half data however. Meanwhile, a NDA during limited
of plan to unmet large expand into We and are our a fast moving area dermatological patient disease. on need orphan new
involving suppurativa thrust of By avacopan inflammatory study primary of the in the indication, will to be under endpoints slide regulatory this which or five, the intend at dieses XX-week controlled disfiguring HS. of see We a avacopan dozens chronic endpoint. with study innovative and end year, randomized with intend of group patients As causes as you The will study into measure benefit skin we new is and large, will from the avacopan of spearhead HS. precedents hidradenitis expansion to and least sites. XXX a launch be patient painful boil-like comparator that a comprehensive into skin. a area, can HS employ nodules disease, per with the specifically
avacopan answer definitive benefit a provide to a provide from as suffering will with to is goal whether patients HS. to therapy Our
We differentiated its are therapy favorable a avacopan of because the potential acquiring mode that as of reminded highly versatile action. a reputation is
complement and neutrophils candidates its leaving the space tissue therapy, and to is the function of immunity. from unique CXa intervention disease-causing alluded I activation rest amplification receptor, targets Avacopan complements of in while drug because selectivity. avacopan the unscathed maintenance As other complement or precisely of earlier, and inflammatory blocking the different
that responsive since designed on pathway, disease, to CXa better the ongoing fact, convenient. in is not does is It tend orally rare beneficial of from CXlX. those is patient actions gratifying trial is or avacopan administered precise It that is second CX medicines our avacopan mechanism avacopan lead this, avacopan an based superbly precise even precise report the glomerulopathy We to receptor, so it that the outcomes. to as effects In well. do shows CXG, a benefit, kidney that history a also additional as performing derive capsule. mechanisms, an the second of protective known of too And deliberately
the placebo avacopan. to cross will Some study, cohort at trial recall group control for in six XX important is comparing heterogeneity months receive our avacopan Enrollment today. of the endpoint a mark halfway expansion is a clinical study, of an you patients. reflecting control to aim CXG Meanwhile, then The a and with this is make of six-month patients over will initial that XX to group about primary of disease. our
can the fact somewhat XX aim We to-date suggests obtain for the randomized mediated important using study, are damage And of in today of include have provide an is individuals group rationale arguably The as avacopan groups measured going We to science, amendment Again, but this not emerging use simple. this of is exhibit is adequately whether intend complement destruction on blood. kidney. as an reflect who These to case activation, the benefit certain measured as in lower amendment controlled answer in that most disease. levels definitive rigorous, question complement designed activation, compassionate our of in case have to suggest, at in CXG a to the what filed the this a in this as may second answer. site patients, XX. two the blood, which CXG complement is
could Kidney slide strikes controlled potentially relapse young. date our the on no after common. are trial transplant for required. CXG. As depicted in randomized regulatory successful often There all such is support often is trial and FDA-approved the X, submissions. from progress And is that to tragically good transplant data We too a CXG believe therapies
and a is function vivo in presented Copenhagen on as are glomerulosclerosis the now Congress described involving novel of lasting, FSGS. of an focus Let in Renal recall, completed focal CCXXXX chemokine segmental and slide And XXth endpoint dosed previously Association program, many kidney as patients Transplant which findings of Dialysis May, Association, with primary disease, renal of CCRX Meeting FSGS glomerulus of a where European kidney seven. on another in the proteinuria clinical At no of in known time. patients our inhibition, Annual CCRX, structure you’ll its disease role approved diabetic significant reduction on receptor normalizing Phase me therapy. orphan in the met devastating targeting underway, second is asset, FSGS, European in CCXXXX, or in X for nephropathy inhibitor improving year’s we in we models continually one trial CCXXXX of another
FSGS. we proteinuria regulatory experience lot reduction key but will that do have because success least to in it with highly this only the not So, two is in reduction on drug the seems syndrome in sub of forms clinical of likely enrolling. patients. at significant, are are be Phase proteinuria approval a another a X FSGS sub-nephrotic in Accordingly, populations we patients One, trial, evaluating with in our nephrotic in and successful primary Patients now currently now some FSGS. primary CCXXXX of building
$XXX to health than that of all pleased this first million and report has been late work, plan. balance Company operations this We running ended stage our financial year never of this pursue than quarter are months the the with favorable exciting six to in sheet. more of Furthermore, we stronger. the I’m As in on more financial took the $XX year our also million
the footprint. global signed approach, over of that June our to call let which to kidney. ChemoCentryx, would the licensing cash includes the Pharma, Vifor further and financial June, CCXXXX to Pharma sell any mid-XXs the The Susan payments rights an in total our disease Vifor teens sales overview quarter Notably, the to a And ChemoCentryx results, sales totaling is an sales accrue avacopan word say and tier territories. Vifor to million additional about Vifor turning me kidney in royalties, In agreement $XX.X provided second with from it China. China rare for and in to percentage. our Pharma especially based derives orphan for upfront of the range Vifor its cumulative we strengthens agreement additional for sales and ascending, streamlines Vifor from diseases Before commercialization in
ChemoCentryx. So, any our to all, for importantly, sales CCXXXX. The in all remind incremental to States. ChemoCentryx commercial retains States large beneficial have a and products free United increases for on rights the accretive, can United ChemoCentryx I’ll impact avacopan energies in Vifor leaves focus all entirely that all market of agreement the
Vifor helps focus on Company. position with our for with with robust era of new a development unique partnership Our value-creation a we us these therapies execute our as enter of Susan? strategy
